Atara extends multi-year collaboration with Be The Match BioTherapies®
Category: #business |   By Pankaj Singh |   Date: 2022-01-08

Atara extends multi-year collaboration with Be The Match BioTherapies®

Atara Biotherapeutics Inc. and Be The Match BioTherapies have reportedly extended their partnership to offer top-quality healthy donor cells for the off-the-shelf T-cell immunotherapy platform of Atara.

The multi-year collaboration uses the abilities of Be The Match BioTherapies to obtain healthy donor cells from the Be The Match Registry® with more than 22 million genetically diverse HLA (human leukocyte antigen) immune profiles.

According to Chris McClain, the Senior Vice President, Sales and Business Development at Be The Match BioTherapies, both companies share the aspiration of serving all patients and this collaboration will enable them to provide treatments to as many patient populations as possible.

Since 2016, Be The Match BioTherapies has been supplying Atara by offering the peripheral blood mononuclear cells, cellular starting material, from healthy donors with specified HLA haplotypes for more production and cryopreservation, with inventory ready to be delivered to needy patients in a few days.

Advanced bioinformatics information into HLS genetics has backed the clinical programs of Atara by assuring that for every product, an inventory of various produced lots is available for partial matching to HLA profiles of patients to bolster safety and efficacy. The regulatory expertise of Be The Match BioTherapies assures the collection of donor cells that cater to FDA as well as international regulations, widening the possible usage of the therapies.

Matt Yedwabnick, the Vice President, Global Supply Chain at Atara, has expressed that the company’s ability to provide study medicines like tab-cel, is reliable in sourcing top-quality healthy donor cells. Be The Match BioTherapies’ abilities have been crucial in recognizing and supplying the starting materials to generate multiple CAR-T and T-cell immunotherapies in development.

Interestingly, Be The Match BioTherapies is the only gene and cell therapy solutions provider with tailored services to bolster the supply chain of end-to-end cell therapy.

Supported by National Marrow Donor Program®/Be The Match®’s industry-leading experience and research collaboration with the Center for International Blood and Marrow Transplant Research® (CIBMTR®), the organization develops solutions that further the development of gene and cell therapies across the world.

Source credit:

https://www.businesswire.com/news/home/20220106005195/en/Be-The-Match-BioTherapies%C2%AE-and-Atara-Biotherapeutics-Announce-Multi-Year-Partnership-Extension

  • shareShare
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh     Twitter

Pankaj Singh

With a commendable experience of content creation under his belt, Pankaj Singh, a qualified Post Graduate in Management, boasts of having worked as a freelance writer and an insurance underwriter. Additionally, Pankaj has also enriched his qualification portfolio with Read more...

More News By Pankaj Singh

Shaurrya Teleservices & Airwaive team up to expand 5G network in India

Shaurrya Teleservices & Airwaive team up to expand 5G network in India

By Pankaj Singh

Airwaive and Shaurrya Teleservices (STS) has reportedly announced an international strategic collaboration to jointly build 5G wireless network service in India, assisting telecom providers in advancing 5G technology throughout the nation. Notably...

Valneva looking to capitalize on growing prevalence of Lyme disease

Valneva looking to capitalize on growing prevalence of Lyme disease

By Pankaj Singh

French drugmaker Valneva SE is now reportedly betting on its vaccine VLA15 for treating climate change-induced Lyme disease, as it looks to capitalize on growing prevalence of tick-borne illnesses following the disappointing sales of its COVID-19 vac...

Reliance Jio becomes the largest buyer of India’s USD 19 Bn 5G sale

Reliance Jio becomes the largest buyer of India’s USD 19 Bn 5G sale

By Pankaj Singh

Reliance Jio Infocomm Ltd., owned by billionaire industrialist Mukesh Ambani, was found to be the most aggressive participant in the government-backed 5G auction in India where several telecom behemoths agreed to invest at least USD 19 billion. Jio w...